| Both sides previous revisionPrevious revision | Both sides next revision |
pharmaceutical_companies:emergent_biosolutions [2022/08/22 00:17]
pamela [Smallpox Vaccine Monopoly] | pharmaceutical_companies:emergent_biosolutions [2022/10/06 02:25] (current)
pamela [COVID-19] |
|---|
| |
| |
| ===== COVID-19 ===== | ===== COVID-19 Vaccines ===== |
| |
| In June 2020, [[AstraZeneca]] and Emergent partnered to manufacture their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Blankenship, K. (2020, June 11). //AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of COVID-19 vaccine.// FiercePharma. https://archive.ph/I1uKJ)) ((Neri, M. B. (2020, June 11). //Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate.// Emergent BioSolutions. https://archive.ph/ivKBp)) In July 2020, Emergent was awarded a five-year contract with [[Johnson & Johnson]] to manufacture a core component of their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Knapp, A. (2021, March 1). //Little-Known Publicly Traded Company Given Massive Deal To Manufacture One-Shot Covid-19 Vaccine.// Forbes. https://archive.ph/FCx7o)) | In June 2020, [[AstraZeneca]] and Emergent partnered to manufacture their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Blankenship, K. (2020, June 11). //AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of COVID-19 vaccine.// FiercePharma. https://archive.ph/I1uKJ)) ((Neri, M. B. (2020, June 11). //Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate.// Emergent BioSolutions. https://archive.ph/ivKBp)) In July 2020, Emergent was awarded a five-year contract with [[Johnson & Johnson]] to manufacture a core component of their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Knapp, A. (2021, March 1). //Little-Known Publicly Traded Company Given Massive Deal To Manufacture One-Shot Covid-19 Vaccine.// Forbes. https://archive.ph/FCx7o)) |
| | |
| | |
| | ==== Manufacturing Disaster ==== |
| | {{ :pharmaceutical_companies:emergent_vaccine_site_shut_down.png?400|}} |
| | FDA orders shutdown at Emergent's troubled plant 2 weeks after handing J&J the keys |
| | April 19, 2021 by Kevin Dunleavy |
| | |
| | Johnson & Johnson’s takeover of COVID-19 vaccine manufacturing at an error-prone Emergent BioSolutions plant in Baltimore didn’t last long. |
| | |
| | Two weeks after the U.S. stepped in and handed control of vaccine manufacturing at the plant to J&J, Emergent agreed to stop producing drug substance there. |
| | |
| | In March, the factory had to discard up to 15 million vaccine doses when it mixed up materials for the J&J and AstraZeneca vaccines. The New York Times reported an additional batch of between 10 million and 15 million doses of the AZ vaccine was lost last November because of suspected contamination at the plant. ((https://web.archive.org/web/20210419145104/https://www.fiercepharma.com/pharma/at-request-fda-emergent-s-troubled-baltimore-plant-suspends-j-j-vaccine-production)) |
